Aptar facility in New Jersey gets controlled substances registration

Aptar Pharma has announced that its facility in Boonton, NJ, USA is now authorized to handle, store, manufacture and test DEA Schedule II and Schedule III controlled substances, adding to existing capacities for handling high potency APIs. Aptar acquired the cGMP facility, which provides formulation and fill and finish services for OINDPs, in 2025 when it acquired Mod3 Pharma (formerly Enteris Biopharma).

The announcement notes that the Boonton facility is part of Aptar Pharma Services, which also includes Nanopharm and human factors specialist Noble. The company has recently announced the appointment of Virginia Maes as its incoming President and the acquisition of Kolibri mesh nebulizer developer Pulmotree.

Aptar Pharma Services Director of Business Development Valerie Otte commented, “Our goal is to make it easier for customers to advance complex and innovative drug products into clinical development. Adding Schedule II-III controlled substance capabilities is another step in building a comprehensive development and manufacturing platform for inhaled and nasal drug products.”

Boonton Site Director Paul Shields said, “This facility has previously handled controlled substances across several dosage forms, so the controls and experience are already well-embedded in our operations. This puts us in a strong position to support a broader range of customer programs while maintaining the highest standards of quality, compliance and security.”

Read the Aptar press release

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

May 30-June 2: ISAM Congress 2027, Dublin, Ireland

June 23: SMI London, London, UK